K-Bio Value Report

[카테고리:] Home

  • Rznomics

    “Beyond RNA 1.0 (Silencing) to RNA 2.0 (Replacement)” Rznomics’ core value lies in its world-first RNA Trans-splicing Ribozyme platform. While traditional RNAi technologies (like siRNA) focus on “cutting and destroying” harmful mRNA, Rznomics focuses on “reprogramming” it. 1. Core Platform: RNA Trans-splicing Ribozyme This technology utilizes a “molecular pair of scissors and glue” that operates…

  • OliX Pharmaceuticals

    OliX Pharmaceuticals is moving beyond the liver to own the “non-liver” RNAi delivery platforms of the future. Its strategy is focused on cp-asiRNA for local delivery, GalNAc for metabolic precision, and BBB-shuttles for CNS targeting. 1. The “cp-asiRNA” Advantage (Ophthalmic & Dermatology) While traditional siRNA requires complex delivery vehicles like LNPs, OliX utilizes a proprietary…

  • Chong Kun Dang (CKD)

    Technical Analysis: The Power of Open Innovation & Commercialization Chong Kun Dang has solidified its position by expertly blending proprietary drug development with strategic in-licensing and open innovation. Its technical value is underpinned by successful commercialization and a robust, diversified pipeline. Technical Deep-Dive: Chong Kun Dang’s Innovation Engine 1. HDAC Platform: The “Precision Scalpel” for…

  • Celltrion

    Celltrion

    Celltrion’s strategy is built on three technological driving forces: SC Formulation (Drug Delivery), Next-Gen ADC (Precision Oncology), and Multispecific Antibodies (Immune Modulation). 1. High-Concentration SC Formulation (The Zymfentra Edge) Celltrion is a global pioneer in Subcutaneous (SC) conversion technology. While most antibody drugs are administered via Intravenous (IV) infusion (taking 2–3 hours in a hospital),…

  • Welcome to K-Bio value analysis web site

    Welcome to K-Bio value analysis web site

    K-Bio Industry Overview: 2025 Performance and 2026 Outlook In 2025, the K-Bio industry demonstrated solid growth, driven by expanding global demand for biopharmaceuticals and the strengthening competitiveness of Korean biotech companies. Exports of biopharmaceutical products increased steadily, supported by large-scale biologics manufacturing, growing biosimilar penetration, and continued progress in innovative drug development. Leading companies showed…